China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q4 2025 earnings summary

Executive summary

• Completed the “14th Five-Year Plan” with enhanced governance and industry leadership, driven by “innovation + brand” strategy amid complex market conditions.

• Significant business expansion through acquisition of a 28% stake in Tian Shi Li, forming a “one body, two wings” structure with CHC, prescription drugs, and traditional Chinese medicine segments.

• R&D investment increased from RMB 581 million in 2020 to RMB 1.734 billion in 2025, with 203 projects in pipeline and 38 new products approved over five years.

• Maintained top position in China’s OTC manufacturer rankings, with 45 products exceeding RMB 100 million in annual sales.

• Cumulative dividends since listing exceed RMB 10 billion, with a payout ratio of 50.59% for 2025.

Financial highlights

• 2025 revenue reached RMB 31.60 billion, up 14.43% year-over-year; net profit attributable to shareholders was RMB 3.42 billion, up 1.58%.

• Operating cash flow was RMB 5.51 billion, up 25.23% year-over-year.

• Basic and diluted EPS were RMB 2.06, with a weighted average ROE of 16.07%.

• Total assets at year-end were RMB 58.80 billion, up 46.71% from the previous year.

• Gross margin for CHC (self-medication) was 61.67%, and for prescription drugs 58.81%.

Outlook and guidance

• 2026 marks the start of the “15th Five-Year Plan,” focusing on innovation, digital transformation, and industry collaboration.

• Plans to invest RMB 2.8 billion in capital expenditures and RMB 6.9 billion in working capital for 2026.

• Revenue growth expected to outpace industry average, with profitability matching revenue growth, barring unforeseen external factors.